PT Millennium Pharmacon International Tbk
Indonesia Stock ExchangeTotal Valuation
PT Millennium Pharmacon International Tbk carries a market capitalization of 229.32B, placing it among publicly traded companies globally. Its enterprise value stands at 1.06T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 229.32B |
| Enterprise Value | 1.06T |
Share Statistics
PT Millennium Pharmacon International Tbk currently has 1.27B shares outstanding.
| Shares Outstanding | 1.27B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
PT Millennium Pharmacon International Tbk trades at a trailing price-to-earnings ratio of 6.43. The price-to-sales ratio is 0.06, and the price-to-book ratio stands at 0.74.
| PE Ratio | 6.43 |
| PS Ratio | 0.06 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | 4.92 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, PT Millennium Pharmacon International Tbk trades at an EV/EBITDA multiple of 9.55 and an EV/FCF ratio of 10.66. The EV/Sales ratio of 0.25 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.55 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.25 |
| EV / EBITDA | 9.55 |
| EV / EBIT | 9.55 |
| EV / FCF | 10.66 |
Financial Position
PT Millennium Pharmacon International Tbk maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 260.99, indicating elevated leverage, while an interest coverage ratio of 1.77 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.11 |
| Quick Ratio | 0.02 |
| Debt / Equity | 260.99 |
| Debt / EBITDA | 7.69 |
| Interest Coverage | 1.77 |
Financial Efficiency
PT Millennium Pharmacon International Tbk posts a return on equity of 12.11 and a return on invested capital of 7.85.
| Return on Equity (ROE) | 12.11 |
| Return on Assets (ROA) | 2.01 |
| Return on Invested Capital (ROIC) | 7.85 |
| Return on Capital Employed (ROCE) | 7.69 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.64 |
Taxes
Over the trailing twelve months, PT Millennium Pharmacon International Tbk has paid 10.28B in income taxes, reflecting an effective tax rate of 21.20.
| Income Tax | 10.28B |
| Effective Tax Rate | 21.20 |
Stock Price Statistics
PT Millennium Pharmacon International Tbk's stock has gained approximately 41.73228% over the past 52 weeks. The 50-day moving average sits at 183.68, while the 200-day moving average is 171.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 41.73228% |
| 50-Day Moving Average | 183.68 |
| 200-Day Moving Average | 171.68 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, PT Millennium Pharmacon International Tbk generated 4.15T in revenue and converted that into 38.24B in net income, yielding earnings per share of 30.01. EBITDA reached 110.48B, while operating income came in at 110.48B.
| Revenue | 4.15T |
| Gross Profit | 361.43B |
| Operating Income | 110.48B |
| Pretax Income | 48.52B |
| Net Income | 38.24B |
| EBITDA | 110.48B |
| EBIT | 110.48B |
| Earnings Per Share (EPS) | 30.01 |
Balance Sheet
PT Millennium Pharmacon International Tbk holds 39.84B in cash and equivalents against 849.53B in total debt, resulting in a net debt position of 809.31B. Total book value stands at 332.31B, with working capital of 175.29B providing operational flexibility.
| Cash & Cash Equivalents | 39.84B |
| Total Debt | 849.53B |
| Net Debt | 809.31B |
| Equity (Book Value) | 332.31B |
| Book Value Per Share | 260.84 |
| Working Capital | 175.29B |
Cash Flow
After subtracting -49.96B in capital expenditures, free cash flow totaled -49.96B - equivalent to -39.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -49.96B |
| Free Cash Flow | -49.96B |
| FCF Per Share | -39.22 |
Margins
PT Millennium Pharmacon International Tbk operates with a gross margin of 8.71, reflecting its pricing power and cost economics. The operating margin of 2.66 and net profit margin of 0.92 provide insight into operational efficiency.
| Gross Margin | 8.71 |
| Operating Margin | 2.66 |
| Pretax Margin | 1.17 |
| Profit Margin | 0.92 |
| EBITDA Margin | 2.66 |
Dividends & Yields
The company's payout ratio of -0.02 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | -0.01 |
| Dividend Yield | N/A |
| Payout Ratio | -0.02 |
| Shareholder Yield | -27.81 |
| FCF Yield | 20.32 |
Stock Splits
PT Millennium Pharmacon International Tbk's most recent stock split took place on November 27, 2017 with a 158:161 split ratio.
| Last Split Date | 11/27/2017 |
| Split Ratio | 158:161 |
Scores
PT Millennium Pharmacon International Tbk posts an Altman Z-Score of 2.64, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.64 |